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ABSTRACT 
 
Uveal melanoma (UM) is a rare intraocular tumor that, similar to cutaneous melanoma, 
originates from melanocytes. To gain insights into its genetics, we performed whole genome 
sequencing at very deep coverage of tumor / control pairs in 33 samples (24 primary and 9 
metastases). Genome-wide, the number of coding mutations was rather low (only 17 
variants per tumor on average; range: 7-28), thus radically different from cutaneous 
melanoma, where hundreds of exonic DNA insults are usually detected. Furthermore, no UV 
light-induced mutational signature was identified. Recurrent coding mutations were found 
in the known UM drivers GNAQ, GNA11, BAP1, EIF1AX, and SF3B1. Other genes, i.e. 
TP53BP1, CSMD1, TTC28, DLK2, and KTN1 were also found to harbor somatic mutations in 
more than one individual, possibly indicating a previously-undescribed association with UM 
pathogenesis. De novo assembly of unmatched reads from non-coding DNA revealed 
peculiar copy number variations defining specific UM subtypes, which in turn could be 
associated with metastatic transformation. Mutational-driven comparison with other tumor 
types revealed that UM is very similar to pediatric tumors, characterized by very few 
somatic insults and, possibly, important epigenetic changes. Through the analysis of whole-
genome sequencing data, our findings shed new light on the molecular genetics of uveal 
melanoma, delineating it as an atypical tumor of the adult for which somatic events other 
than mutations in exonic DNA shape its genetic landscape and define its metastatic 
potential. 
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 Despite having the very rare incidence of 5-8 new cases per million per year,1,2 uveal 
melanoma (UM [MIM: 155720]) is the most common primary intraocular tumor of the adult. 
It develops from melanocytes in the choroid, the ciliary body, or the iris (collectively called 
the "uvea", one of the inner layers of the eye) and usually metastasizes through the blood 
stream to the liver.3,4 Symptoms include variable and painless visual disturbances, often 
presenting when the tumor has already reached a considerable mass. Survival and potential 
therapeutic options depend, among other things, on the presence of specific genetic 
alterations.5 While population studies suggest ethnic predisposition,6,7 environmental 
factors that are directly involved in the transformation process have not been clearly 
delineated. For instance, a possible association with UV light exposure has been suggested,8-
11 but questioned recently by molecular data.12 Research on UM molecular genetics has 
been performed mostly by investigating coding mutations or copy number variations 
detectable by direct sequencing of target genes, karyotype, array-CGH, MLPA, or SNP-array 
analyses.13-17 As a result, mutations at codon 209 of the paralogous oncogenes GNAQ [MIM: 
600998] and GNA11 [MIM: 139313]18,19 and in the tumor suppressor BAP1 [MIM: 603089]20 
have been identified in the majority of UMs, whereas insults in EIF1AX [MIM: 300186] and 
SF3B1 [MIM: 605590] or other genes seem to be less frequent, accounting for at most 20% 
of cases.12,21-26 Moreover, copy gains and losses are common events in this tumor, typically 
involving chromosome 3 monosomy, 6p gain, and 8q gain.14,17 Following whole-genome 
sequencing of a series of tumor-control pairs, we present here an analytically unbiased and 
comprehensive assessment of the genetic landscape of UM. 
 We screened 33 UM samples (24 primary tumors and 9 unrelated metastases, Table 
S1) and corresponding normal tissue pairs by deep coverage whole-genome sequencing 
(WGS), using the sequencing platform by Complete Genomics.27 Written informed consent 
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was obtained from all individuals enrolled in this study, and approval for human subject 
research was obtained from the Institutional Review Boards of all participating Institutions. 
Sequence reads were mapped to the human reference genome, assembly GRch37, and 
somatic variants in tumors were called by comparison with the matched normal genomes, 
as previously described.28 All samples were surgically collected from eye enucleations or 
resected from liver metastases, allowing very clear post-surgery macroscopic isolation of 
tumor tissue from the surrounding environment. None of the 33 affected individuals 
received any treatment prior to primary tumor removal. Average coverage was 112x (range: 
102-118) for both tumor and control samples (>96% of the genome was covered 40x or 
more times), with minimal inter-individual variations (not shown). Mutation calls were 
performed genome-wide and included single-nucleotide variants (SNVs), copy number 
variations (CNVs), as well as structural variations (SVs) such as chromosomal 
rearrangements. CNVs and SVs were assessed by comparing sequence coverage and 
especially de novo assembly of reads defining novel genetic junctions.28 Data were extracted 
from MasterVar files and other relevant matrices by ad hoc Perl, bash, and R scripts, 
available upon request. Overall, we detected 37,321 SNVs (average per sample: 1,166; 
range: 576-2,131), 1,584 SVs (average per sample: 50, range: 13-182), and a number of 
CNVs corresponding to an average of 13.6% of the genome (range: 0.03-33.9%) (Table S2). 
 Unsupervised hierarchical clustering of our samples on CNVs revealed four major 
subgroups associated with mutational and metastatic status, branched two by two (Figure 
1). Classes A and B (first branch) involved samples carrying chromosome 3 monosomy (by 
Fisher test, p-value=4.4x10-06), chr 8q gain (p-value=2.8x10-09), and in some instances chr 8p 
loss (p-value=3.0x10-02). In addition, class B tumors also had loss of chr 6q (p-value=1.0x10-
03). Conversely, classes C and D represented more distinct subtypes with relatively few 
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chromosomal rearrangements; class C tumor had no major aneuploidies, whereas class D 
reported gains of the distal part of chr 8q (p-value=2.0x10-03). Seven samples presenting chr 
1q gain were scattered across all classes, whereas loss of chr 1p were typical of class A 
tumors (p-value=5.0x10-03). 
 Samples with monosomy of chr 3 were also associated (77% of cases) with somatic 
mutations in the tumor suppressor BAP1, lying on chr 3p21.1, in accordance with Knudson’s  
two-hit model of tumorigenesis.29 Indeed, BAP1 SNVs included all kinds of somatic events, 
but mostly mutations leading to premature stop codons and therefore to functional protein 
knockout (Figure S1, Table S3). Hallmark driver mutations in the GNAQ and GNA11 
paralogues, encoding the components of the alpha subunit of the Gq protein heterotrimer, 
were present in 100% of the samples examined. They occurred in a perfectly mutually 
exclusive pattern and involved only four specific missenses: c.626A>T (p.Gln209Leu) [NCBI 
RefSeq: NM_002072.4] (11 samples) and c.626A>C (p.Gln209Pro) [NCBI RefSeq: 
NM_002072.4] (8 samples) in GNAQ, and c.626A>T (p.Gln209Leu) [NCBI RefSeq: 
NM_002067.4] (13 samples) and c.626A>C (p.Gln209Pro) [NCBI RefSeq: NM_002067.4] (1 
sample) in GNA11, affecting the same functional amino acid residue and conferring 
oncogenic potential to this G protein.18,19 Six tumors (18%) had missense mutations in SF3B1 
(Splicing Factor 3B, subunit 1), affecting codon 625 (5 cases) and codon 626 (1 case) (Figure 
S1, Table S3), a previously described hotspot region.21 Finally, 7 other tumors had mutations 
impacting the first 10 codons of EIF1AX (Eukaryotic Translation Initiation Factor 1A, X-
Linked) (Figure S1, Table S3).22 Mutations in SF3B1 and EIF1AX seemed to occur in a 
mutually exclusive pattern and to be enriched classes C and D (p-value=1.6x10-4), with SF3B1 
preferentially mutated in class D. Except for one sample, BAP1 mutations were never 
observed in cases carrying mutations in SF3B1 or EIF1AX (p-value= 1.4x10-5), in agreement 
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with findings from previous literature.23,30 Also, consistent with the fact that all of the 
tumors analyzed harbored variants affecting either GNAQ or GNA11 Gln209, no somatic 
SNVs were observed in PLCB4 or CYSLTR2, two genes that have been found to be mutated in 
a mutually exclusive pattern with respect to GNAQ or GNA11 variants.25,26  
 Five genes (TP53BP1 [MIM: 605230], CSMD1 [MIM: 608397], TTC28 [MIM: 615098], 
DLK2 [MIM: N/A], and KTN1 [MIM: 600381]) harbored somatic missense or truncating 
mutations in at least two samples, across all tumor classes (Table S3). No other non-
synonymous SNVs affecting coding regions of the genome were present in more than two 
samples. TP53BP1 is a partner of the tumor suppressor protein p53, known to play a crucial 
role in maintaining genomic integrity as a mediator and effector of homologous 
recombination in response to double-strand breaks. This protein acts as a molecular scaffold 
that recruits responsive proteins, in order to repair damaged chromatin31 and its depletion 
has been associated with increased cell proliferation.32 CSMD1 (Cub and Sushi Multiple 
Domains-1) is a candidate tumor suppressor gene, the hyper-expression of which increased 
survival in mice with xenografted tumors.33 Loss of CSMD1 was detected in a large set of 
cancers, including head and neck, lung, breast and skin primary tumors,34 and associated 
with high tumor grade in invasive ductal breast carcinoma.35 TTC28 (Tetratricopeptide 
Repeat Domain 28) is a ubiquitous protein, associated with diverse biological functions. Of 
note, TCC28 plays a critical role in the progress of mitosis and cytokinesis during mammalian 
cell cycle and its dysfunction was described as a potential component of tumorigenesis and 
tumor progression.36,37 DLK2 (Delta-Like 2 homolog) is a transmembrane epidermal growth 
factor-like protein. It is highly homologous to DLK1, a protein that was found to be present 
at high levels in gliomas and involved in cell proliferation.38 Similar to DLK1, DLK2 can bind to 
NOTCH1,39 modulating the oncogenic potential of cultured melanoma cells.40 Finally, KTN1 
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(Kinectin 1) is a protein of the endoplasmic reticulum membrane that interacts with 
kinesins.41,42 Its role in cancer may be linked to dysregulation of cytoskeletal activity and 
mitosis. Two of these five genes were previously found to be mutated in UM: a missense in 
TTC28 was detected in one out 35 samples from a WES screen,22 while the cBioPortal 
repository reports a missense mutation in KTN1 in one out of 80 tumors profiled by 
TCGA.43,44 
 Taken together, our clustering analysis indicates that initial events involve GNAQ or 
GNA11 mutations, followed by a major branching determined by the functional loss of BAP1 
and copy gains of chr 8q vs. cases with a relatively normal chromosomal ploidy. These latter 
samples have conversely mutations in EIF1AX or in SF3B1 (classes A and B vs. C and D, 
respectively). In BAP1-negative samples, the long arm of chr 6 could eventually be lost, 
differentiating class B from class A. In BAP1-positive tumors, part of chr 8q could undergo 
amplification, differentiating class D from class C (Figure 2). 
 Aggregate analyses on genetic data showed no significant differences between 
primary (PUM) and metastatic UM (MUM) samples, in terms of number of somatic coding 
SNVs, non-coding SNVs, CNVs, and SVs, indicating that the extent of genomic instability was 
here not associated with metastatic potential (Figure 3B-E). Although singularly none of the 
main somatic drivers (chr 3, 6q, and 8q aneuploidies, as well as SNVs in BAP1, GNAQ, 
GNA11, SF3B1, EIF1AX) were computed as being statistically different, enrichment in PUMs 
vs. MUMs showed very clear association trends (Figure 3A). 
 Remarkably, when considering specific levels of 8q amplification detectable by 
algorithms querying non-coding WGS data for CNVs and aneuploidies, we found a very clear 
association between metastatic potential and 8q ploidy of 5 copies or more (p-value=8.6x10-
4, Figure 3A). In addition, single-copy amplification of 8q (ploidy=3) was indeed associated 
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with primary tumors (p-value=4.7x10-3, Figure 3A). Similarly, when mutational sets defining 
tumor sub-classes were considered, a significant association between sub-class B and 
metastases was identified (Figure 1, p-value=2.0x 10-2). 
 With respect to metastatic samples, the aneuploidies identified correlated well with 
those of 66 liver metastases from UM investigated previously, detecting chr 3 monosomy 
(73%), 8q gain (89%), 6q loss (64%), 1p loss (47%), 8p loss (45%), 1q gain (35%) and 16q loss 
(32%).14 Similarly, the identified SNVs matched those on another study on 5 liver 
metastases.45 Finally, the identification of a SF3B1 mutation in one metastatic sample from 
our series is also in line with late-onset metastasis occurring in individuals with SF3B1 
mutations.23 
 Mutations targeting BAP1 are one of the genetic landmarks of UM20 and were found 
here to be associated with classes A and B (p-value=1.2x10-4), classes that are in fact defined 
mostly by the presence of chr 3 monosomy. To test for functional inactivation of the BAP1 
protein, we assessed its nuclear staining in histological sections of all tumors (Figure 4). 
Twenty of the 33 samples (60%) displayed loss of nuclear localization (Figure 4). Of these, 17 
(85%) presented chr 3 monosomy and a coding SNV (a truncating SNV in 14 cases and a 
missense or an in-frame deletion in 3 cases), accounting for loss of heterozygosity and 
protein delocalization. 
 The number of somatic SNVs involving coding and non-coding regions was strikingly 
low (Figure S2). Globally, the average load of coding mutations was 0.24/Mb (range: 0.08-
0.42/Mb, Table S4), one of the lowest detected so far in tumors. Comparison with other 
cancer types revealed that UM mutational load for coding regions was closer to that of 
pediatric tumors such as rhabdoid tumors [MIM: N/A], medulloblastoma [MIM: 155255], 
neuroblastoma [MIM: N/A], etc.,46 rather than that of adult cancers (Figure S3). Pediatric 
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tumors typically develop over a shorter period than most adult malignancies, frequently 
harbor few driver mutations, and may thereby have fewer sources of heterogeneity, 
facilitating the assessment of both the genetic and epigenetic determinants underlying their 
pathogenesis. Our data seem to suggest that, similarly to pediatric tumors, UM 
development may rely more on epigenetic drivers of transformation and tumor progression, 
rather than the classical accumulation of genetic events observed in the vast majority of 
adult malignancies. 
 The number of non-coding SNVs was also relatively low (736 per tumor on average, 
range: 371-1347) and mostly proportional to the number of coding SNVs (17 per tumor on 
average, range: 7-28) (Figure S2), confirming that, compared to both cutaneous and 
conjunctival melanomas, which also originate from melanocytes, UM follows a different 
oncogenic pathway, characterized by significantly fewer mutations.47,48 In addition, we 
failed to identify any statistically relevant non-coding SNVs for tumor-specific sites that were 
present in four samples or more, suggesting the absence of common regulatory variants in 
the landscape of these tumors, at least in our cohort. 
 Another difference between UM and cutaneous and conjunctival melanomas 
involved its mutational spectrum (Figure 5). Analysis of all coding and non-coding somatic 
single-nucleotide substitutions (SNSs) from our series showed the clear absence of an UV-
induced mutation signature. This particular spectrum results from sunlight-driven formation 
of pyrimidine dimers on the DNA49 and is found in both cutaneous and conjunctival 
melanomas.47,48 Direct analysis of genes known to be involved in cutaneous melanoma, such 
as BRAF [MIM: 164757], NRAS [MIM: 164790], and NF1 [MIM: 162200] revealed no somatic 
mutations in UM, supporting again the notion that uveal and cutaneous melanomas have a 
different molecular etiology.50,51 Conversely, the UM mutational spectrum was remarkably 
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similar across all PUMs and MUMs and resembled that of apparently unrelated tumors, such 
as clear cell renal carcinoma, thyroid tumor, and glioblastoma (Figure 6). Notably, despite a 
different cellular origin, UM shares with these tumors recurrent genetic modifications; BAP1 
mutations and chr 3 monosomy are frequently seen in clear cell renal carcinoma,52 while 
hotspot mutations in the first codons of EIF1AX are recurrent in papillary thyroid 
carcinoma.53 
 Analysis of all specific SNS types along with composition of the flanking bases 
allowed determining specific mutational signatures for UM, according to the classification of 
Alexandrov et al.54 Our samples appeared to be enriched for signatures 12 or 16 (55% of the 
score), signature 1B (25%), and signature 6 (20%) (Figure 5B). Signature 1B corresponds to a 
rather ubiquitous pattern in cancer, resulting from the spontaneous deamination of 5-
methyl-cytosine, which in turn is thought to correlate with the process of aging.54,55 
Conversely, signatures 12/16 and 6 are associated with defects in nucleotide excision repair 
and DNA mismatch repair, respectively. 
 A more global approach, considering the intersection between the SNVs detected in 
our series and the most frequently mutated genes in cancer (TCGA PANCAN list)56 also 
revealed a minimal overlap, limited to BAP1 and SF3B1 (Figure S4). 
 A non-negligible number of structural variants (SVs) such as deletions, duplications, 
inversions, or inter and intra chromosomal rearrangements were also observed (Figure S5). 
Only a few of these events were recurrent, indicating the absence of major common drivers 
constituted by genetic events involving large parts of the genome. Among these, however, 
there were three inter-chromosomal events that were present in at least two individuals 
(Figure 7). Three samples (PUM20, PUM18 and PUM5) had a translocation involving chr 6 
and chr 8 disrupting UBE2W [MIM: 614277] and MYO6 [MIM: 600970] for the 2 first 
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samples, respectively. The third event occurred in intergenic regions. Translocations 
between chr 13 and chr 17 (no genes involved) were also present in MUM9 and PUM5, and 
between chr 3 and chr 12 in PUM17 (no genes involved) and in PUM5 (disrupting KDM2B 
[MIM: 609078]) (Table S5). Although these translocations impacted roughly the same 
genomic areas, highlighting possible hotspot regions in UM genome, they neither targeted 
the same genes nor defined a specific tumor sub-category. Of note, one individual (PUM5) 
appeared to harbor a higher number of interchromosomal events and SVs than the average 
value of the other cases (Figure S5). Notably, this individual was also an outlier of our 
clustering analysis (Figure 1). However, neither the medical history nor tumor pathology 
revealed any uncommon feature, compared to the rest of the cohort. 
 Amplification of chr 8q is a well-known and important feature of UM.17,57,58 Levels of 
chr 8q amplification seem to define prognostic status and metastatic potential in UM and 
differentiate class C from D (Figures 1 and 2). However, the molecular bases for this 
phenomenon are not known. One possible explanation is that the amplification is driven by 
the MYC oncogene [MIM: 190080], which lies in this region.59 By comparing the pattern of 
chr 8q amplification in our samples, we determined the minimal region of overlap, involving 
a 2.3 Mb fragment towards its telomeric site (chr8:126,404,000-128,682,000). 
 Surprisingly, this region was very close to MYC (chr8: 128,748,314-128,753,680) but 
did not include it. Conversely, it harbored 6 other genes (POU5F1B [MIM:615739], FAM84B 
[MIM: 609483], TRIB1 [MIM: 609461], LOC100130231/LINC00861 [MIM: N/A], 
LOC100507056/CCAT1 [MIM: N/A], and LOC727677/CASC8 [MIM: N/A]). The most 
interesting of them was POU5F1B (POU Class 5 Homeobox 1B), a pseudogene of the 
POU5F1/OCT4 family, recently involved in prostatic and gastric cancer.60,61 Real-Time 
quantitative PCR experiments showed that only POU5F1B, TRIB1, LINC00861, and CCAT1 
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were expressed in our UM samples, but no statistically significant correlation between their 
expression levels and 8q amplification or tumor class could be detected. The same held true 
for the MYC transcript, suggesting that none of these genes play a key role in UM 
pathogenesis (Figures S6-S7). 
 By using a WGS-based, untargeted approach to investigate the genetic components 
of UM, we had the unique opportunity of assessing its genomic landscape as a whole, from 
single nucleotide variants to interchromosomal rearrangements, providing the bases for 
future functional studies that go beyond the scope of our analysis. The global picture 
emerging from our work indicates that, genetically, UM is a relatively atypical tumor, mostly 
in virtue of the paucity of somatic events that characterize it. Driver mutations are very few 
and are confined to a relatively low number of genes, such as BAP1, GNAQ and GNA11. 
Other genes, including those that were identified in this study, may have a role in 
tumorigenesis, but they are nonetheless present in a small fraction of the tumors studied. 
Conversely, larger events such as extended copy number and structural variations seem to 
shape  UM’s  genome  in  a  much  more  relevant  way,  possibly  determining  tumor  progression  
and fate. Taken together, our results point to a critical role for non-canonical mechanisms of 
cellular transformation in UM development, where chromosomal rearrangements, silencing 
of chromatin regulators (e.g. BAP1), and non-coding SNVs potentially affecting distal 
regulatory elements may collaborate in the establishment of a permissive oncogenic 
landscape. 
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LEGENDS TO FIGURES 
 
Figure 1. Unsupervised hierarchical clustering and global genetic landscape of all 
tumors analyzed in this study. Samples IDs are indicated on the right. CNV events are 
depicted in blue (copy losses) or in shades of red (copy gains) and ploidy is indicated in the 
legend provided at the top. SNVs in genes found to carry mutations in six or more 
individuals are shown on the left, with mutation classes provided within grey boxes. 
Clustering identifies 4 classes: A, B, C, and D (see text), indicated within the dendrogram. 
 
Figure 2. Inferred somatic events defining tumor classes, as identified by clustering. 
Colors are the same as those shown in Figure 1. All steps determining branching are 
statistically significant. 
 
Figure 3. Genetic features in Primary (PUM) and Metastatic (MUM) tumors. (A) 
Overview of all major somatic events with respect to PUMs and MUMs. Each circle indicates 
a specific genetic event; its center corresponds to the percentage of samples carrying this 
feature in PUMs vs. MUMs, whereas its diameter indicates the total number of such 
samples. Asterisks indicate statistical significance. The grey area depicts the surface of the 
plot for which there is an enrichment in MUMs. (B-E) Box plots of different types of genetic 
alterations, at the genome-wide scale. 
 
Figure 4. Landscape of genetic alterations involving BAP1, and 
immunohistochemistry of BAP1 protein. (A) Samples are ordered with respect to 
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absence/presence of BAP1 nuclear localization, indicating loss or preservation of protein 
function, respectively. In general, loss of BAP1 function correlates with presence of a 
somatic SNV and loss of heterozygosity. (B and C) Representative micrographs of paraffin-
embedded UM samples showing absence and presence of BAP1 protein, respectively. 
Magnification: 252 x. 
 
Figure 5. Mutational signature of our samples, for SNSs, genome-wide. (A) Main 
graph: comparison of mutational load of the UM samples studied with respect to two 
melanomas of the conjunctiva (CM), sequenced and processed according to the same 
methods.48 The number of mutations is radically different in UM vs. CM. Inset: mutational 
spectrum of each UM sample, in percentage, showing a relatively homogeneous spectrum. 
(B) Results of the analysis of mutational events according to the methods and the 
classification proposed by Alexandrov et al.54,55 Three main signatures are detected in our 
samples,  evocative  of  Alexandrov’s signatures 12/16, 1B, and 6. The different peaks indicate 
specific genetic contexts of the altered nucleotide and are ordered according to the original 
article.54 
 
Figure 6. Analysis of the mutational spectrum in our samples vs. other cancer types, 
in coding regions only. (A) The spectrum from UM is dissimilar from those from cutaneous 
and conjunctival melanomas, which are dominated by UV light-induced events (C to T 
transitions) and is conversely closer to that of thyroid and renal papillary cancer. (B) 
Principal component analysis (PCA) of the same data, showing the relatedness of UM with a 
few cancers but again, not with other melanomas. Dimensions of the PCA are indicated by 
the arrowed axes. Primary data other than UM are from previously-published sources.48,62 
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Cancer types: aLung: Lung – adenocarcinoma, scLung: Lung – squamous cell, pRenal: Renal - 
papillary, ccRenal: Renal – clear cell, GBM: Glioblastoma multiforme, AML: Acute myeloid 
leukemia, Cut_mel: Cutaneous melanoma, CM: Conjunctival melanoma. 
 
Figure 7. Circos plot of all somatic interchromosomal events, in all UM samples. Red 
lines indicate events involving the same chromosomal regions in more than two individuals. 
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